BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang WT, Lu HI, Wang YM, Chen YH, Lo CM, Lin WC, Lan YC, Tseng LH, Li SH. Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy. J Clin Med 2019;8:E1864. [PMID: 31684197 DOI: 10.3390/jcm8111864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Liu J, Cai XW, Li HX, Cheng Y, Dong XH, Yu W, Fu XL. Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: A systemic review. Crit Rev Oncol Hematol 2021;167:103466. [PMID: 34508841 DOI: 10.1016/j.critrevonc.2021.103466] [Reference Citation Analysis]
2 Zhang C, Luo Y, Zhang Z, Zhang Z, Zhang G, Wang F, Che Y, Fang L, Zhang Y, Sun N, He J. Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes. Front Cell Dev Biol 2020;8:580005. [PMID: 33392181 DOI: 10.3389/fcell.2020.580005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Zhang W, Wang P, Pang Q. Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. Ann Transl Med 2020;8:1193. [PMID: 33241042 DOI: 10.21037/atm-20-4625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zhang F, Zhu X, Zhang Q, Zhou P, Hao L. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy. Aging (Albany NY) 2021;13:18827-38. [PMID: 34297698 DOI: 10.18632/aging.203326] [Reference Citation Analysis]
5 He W, Leng X, Wang K, Mao T, Peng L, Fang Q, Xiao W, Han Y. Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol 2020;11:1105-12. [PMID: 33456985 DOI: 10.21037/jgo-20-504] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]